An article offering new insights into meningioma has been published by Professor Oliver Hanemann and the research team at our Centre of Excellence at the University of Plymouth.
Meningioma are the most common form of adult primary brain tumour, but gaps in our understanding of the way they develop means that the management of this tumour type remains complicated. Without an improved understanding, effective treatments for aggressive meningioma are unlikely to be found.
The study aimed to outline the differences in the molecular landscape between high-grade and low-grade meningioma. It has been used to deliver valuable insights into the altered gene expression profile between high and low-grade meningioma.
In addition, the team’s findings identified molecules that may hold potential as biomarkers or therapeutic targets of high-grade meningioma.
The article, titled “Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma” forms part of the route to a better molecular knowledge of meningioma.
You can read the full article here.
Related reading:
If you found this story interesting or helpful, sign up to our weekly e-news and keep up to date with all the latest from Brain Tumour Research.